Evidence map›Paper›PMID 34790011›Full record

ReviewWorld journal of gastroenterology2021

Management of hepatitis B and C in special population.

Anand V Kulkarni, Nageshwar Reddy Duvvuru

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. An update on the genetics of alcoholic liver disease.Frontiers in gastroenterology (Lausanne, Switzerland) · 2022
    Review
  2. Management of Portal Hypertension.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Anand V KulkarniDepartment of Hepatology, Asian Institute of Gastroenterology, Hyderabad 500032, Telangana, India. anandvk90@gmail.com.
Nageshwar Reddy DuvvuruDepartment of Gastroenterology, Asian Institute of Gastroenterology, Hyderabad 500032, Telanagana, India.
Asian Institute of Gastroenterology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic viral hepatitis is one of the leading causes of cirrhosis worldwide. Chronic hepatitis B is more common in the Asia-Pacific region due to the larger population and lower screening availability. Hepatitis C predominates in the west due to injection drug abuse. The discovery of (oral) direct-acting antiviral agents (DAAs) has changed the landscape of chronic hepatitis C (CHC) management. Nucleos(t)ide analogs (NUCs) have also changed the approach to the treatment of chronic hepatitis B (CHB). Oral NUCs and DAAs have excellent efficacy and patient acceptance as well as a lower risk of resistance. However, certain populations have no robust data and safety and efficacy of such oral drugs is still evolving. In this review, we provide an overview of the management of CHB and CHC in special populations, such as those with chronic kidney disease, pregnant women, healthcare workers, and those undergoing chemo- or immunosuppressive therapy.

Indexed as

Hepatitis BHepatitis B, ChronicHepatitis C, ChronicAntiviral AgentsFemaleHepatitis B e AntigensHepatitis B virusHumansPregnancyTreatment OutcomeAntiviral AgentsHepatitis B e AntigensChronic kidney diseaseHealth care professionalsHepatitis BHepatitis CPregnancyTenofovir

Identifiers

PMID34790011
PMCPMC8567468
OpenAlexW3211115607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.